Eli Lilly: Number of Employees 2010-2024 | LLY

Interactive chart of Eli Lilly (LLY) annual worldwide employee count from 2010 to 2024.
  • Eli Lilly total number of employees in 2023 was 43,000, a 10.26% increase from 2022.
  • Eli Lilly total number of employees in 2022 was 39,000, a 11.43% increase from 2021.
  • Eli Lilly total number of employees in 2021 was 35,000, a 0% decline from 2020.
  • Eli Lilly total number of employees in 2020 was 35,000, a 4.09% increase from 2019.
Eli Lilly Annual Employee Count
2023 43,000
2022 39,000
2021 35,000
2020 35,000
2019 33,625
2018 38,680
2017 40,655
2016 41,975
2015 41,275
2014 39,135
2013 37,925
2012 38,350
2011 38,080
2010 38,350
2009 40,360
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $749.124B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $479.942B 34.61
Johnson & Johnson (JNJ) United States $353.006B 14.32
AbbVie (ABBV) United States $306.369B 16.13
Merck (MRK) United States $258.023B 17.14
AstraZeneca (AZN) United Kingdom $206.438B 17.57
Novartis AG (NVS) Switzerland $201.048B 13.36
Pfizer (PFE) United States $144.962B 9.91
Sanofi (SNY) $118.770B 10.76
Innoviva (INVA) United States $1.163B 9.68